Inhibition of topoisomerase II by phase II metabolites of resveratrol in human colon cancer cells

Molecular Nutrition and Food Research

Volumn 59, Issue 12, 2015, Pages 2448-2459

  Schroeter, Anika ^a   Groh, Isabel Anna Maria ^a   Del Favero, Giorgia ^a   Pignitter, Marc ^a   Schueller, Katharina ^a   Somoza, Veronika ^a   Marko, Doris ^a  

^a UNIVERSITY OF VIENNA   (Austria)

Author keywords

Colon cancer cells; DNA damage; Resveratrol; Resveratrol metabolites; Topoisomerase

Indexed keywords

GLUCURONIDE; GYRASE INHIBITOR; RESVERATROL; RESVERATROL-3-O-4'-DISULFATE; RESVERATROL-4'-O-GLUCURONIDE; STILBENE DERIVATIVE;

APOPTOSIS; CACO-2 CELL LINE; CELL FREE SYSTEM; COLONIC NEOPLASMS; COMET ASSAY; DRUG EFFECTS; DRUG SCREENING; HT-29 CELL LINE; HUMAN; METABOLISM; PROCEDURES;

APOPTOSIS; CACO-2 CELLS; CELL-FREE SYSTEM; COLONIC NEOPLASMS; COMET ASSAY; DRUG SCREENING ASSAYS, ANTITUMOR; GLUCURONIDES; HT29 CELLS; HUMANS; STILBENES; TOPOISOMERASE II INHIBITORS;

EID: 84954339072     PISSN: 16134125     EISSN: 16134133     Source Type: Journal    
DOI: 10.1002/mnfr.201500352     Document Type: Article

References (40)

1. Langcake, P., Pryce, R. J., The production of resveratrol by Vitis vinifera and other members of the Vitaceae as a response to infection or injury. Physiol. Plant Pathol. 1976, 9, 77-86.
2. Baur, J. A., Sinclair, D. A., Therapeutic potential of resveratrol: the in vivo evidence. Nat. Rev. Drug Discov. 2006, 5, 493-506.
3. Leone, S., Basso, E., Polticelli, F., Cozzi, R., Resveratrol acts as a topoisomerase II poison in human glioma cells. Int. J. Cancer 2012, 131, E173-E178.
4. Baechler, S. A., Schroeter, A., Dicker, M., Steinberg, P. et al., Topoisomerase II-targeting properties of a grapevine-shoot extract and resveratrol oligomers. J. Agric. Food Chem. 2014, 62, 780-788.
5. Schroeter, A., Marko, D., Resveratrol modulates the topoisomerase inhibitory potential of doxorubicin in human colon carcinoma cells. Molecules 2014, 19, 20054-20072.
6. Pommier, Y., Leo, E., Zhang, H., Marchand, C., DNA topoisomerases and their poisoning by anticancer and antibacterial drugs. Chem. Biol. 2010, 17, 421-433.
7. Nitiss, J. L., Targeting DNA topoisomerase II in cancer chemotherapy. Nat. Rev. Cancer 2009, 9, 338-350.
8. Delmas, D., Aires, V., Limagne, E., Dutarte, P. et al., Transport, stability, and biological activity of resveratrol. Ann. N. Y. Acad. Sci. 2011, 1215, 48-59.
9. Gescher, A. J., Steward, W. P., Relationship between mechanisms, bioavailibility, and preclinical chemopreventive efficacy of resveratrol: a conundrum. Cancer Epidemiol. Biomarkers Prev. 2003, 12, 953-957.
10. Boocock, D. J., Faust, G. E., Patel, K. R., Schinas, A. M. et al., Phase I dose escalation pharmacokinetic study in healthy volunteers of resveratrol, a potential cancer chemopreventive agent. Cancer Epidemiol. Biomarkers Prev. 2007, 16, 1246-1252.
11. Walle, T., Bioavaibility of resveratrol. Ann. N. Y. Acad. Sci. 2011, 1215, 9-15.
12. Brown, V. A., Patel, K. R., Viskaduraki, M., Crowell, J. A. et al., Repeat dose study of the cancer chemopreventive agent resveratrol in healthy volunteers: safety, pharmacokinetics, and effect on the insulin-like growth factor axis. Cancer Res. 2010, 70, 9003-9011.
13. Burkon, A., Somoza, V., Quantification of free and protein-bound trans-resveratrol metabolites and identification of trans-resveratrol-C/O- onjugated diglucuronides-two novel resveratrol metabolites in human plasma. Mol. Nutr. Food Res. 2008, 52, 549-557.
14. Boocock, D. J., Patel, K. R., Faust, G. E., Normolle, D. P. et al., Quantitation of trans-resveratrol and detection of its metabolites in human plasma and urine by high performance liquid chromatography. J. Chromatogr. B 2007, 848, 182-187.
15. Patel, K. R., Brown, V. A., Jones, D. J., Britton, R. G. et al., Clinical pharmacology of resveratrol and ist metabolites in colorectal cancer patients. Cancer Res. 2010, 70, 7392-7399.
16. Wenzel, E., Soldo, T., Erbersdobler, H., Somoza, V., Bioactivity and metabolism of trans-resveratrol orally administered to Wistar rats. Mol. Nutr. Food Res. 2005, 49, 482-494.
17. Gualdoni, G. A., Kovarik, J. J., Hofer, J., Dose, F. et al., Resveratrol enhances TNF-α production in human monocytes upon bacterial stimulation. Biochim. Biophys. Acta 2014, 1840, 95-105.
18. Patel, K. R., Andreadi, C., Britton, R. G., Horner-Glister, E. et al., Sulfate metabolites provide an intracellular pool for resveratrol generation and induce autophagy with senescence. Sci. Transl. Med. 2013, 5, 205ra133, 1-12.
19. Walker, J., Schueller, K., Schaefer, L. M., Pignitter, M. et al., Resveratrol and its metabolites inhibit pro-inflammatory effects of lipopolysaccharides in U-937 macrophages in plasma-representative concentrations. Food Funct. 2014, 5, 74-84.
20. Hoshino, J., Park, E.-J., Kondratyuk, T. P., Marler, L. et al., Selective synthesis and biological evaluation of sulfate-conjugated resveratrol metabolites. J. Med. Chem. 2010, 53, 5033-5043.
21. Aires, V., Limagne, E., Cotte, A. K., Latruffe, N. et al., Resveratrol metabolites inhibit human metastatic colon cancer cells progression and synergize with chemotherapeutic drugs to induce cell death. Mol. Nutr. Food Res. 2013, 57, 1170-1181.
22. Polycarpou, E., Meira, L. B., Carrington, S., Tyrrell, E. et al., Resveratrol 3-O-d-glucuronide and resveratrol 4'-O-d-glucuronide inhibit colon cancer cell growth: evidence for a role of A3 adenosine receptors, cyclin D1 depletion, and G1 cell cycle arrest. Mol. Nutr. Food Res. 2013, 57, 1708-1717.
23. Walle, T., Hsieh, F., DeLegge, M. H., Oatis, J. E., Jr. et al., High absorption but very low bioavailability of oral resveratrol in humans. Drug Metab. Dispos. 2004, 32, 1377-1382.
24. van de Wetering, K., Burkon, A., Feddema, W., Bot, A. et al., Intestinal breast cancer resistance protein (BCRP)/Bcrp1 and multidrug resistance protein 3 (MRP3)/Mrp3 are involved in the pharmacokinetics of resveratrol. Mol. Pharmacol. 2009, 75, 876-885.
25. Tice, R. R., Agurell, A., Anderson, D., Burlinson, B. et al., Single cell gel/comet assay: guidelines for in vitro and in vivo genetic toxicology testing. Environ. Mol. Mutagen. 2000, 35, 206-221.
26. Gehrke, H., Fruhmesser, A., Pelka, J., Esselen, M. et al., In vitro toxicity of amorphous silica nanoparticles in human colon carcinoma cells. Nanotoxicology 2013, 7, 274-293.
27. Colin, D., Lancon, A., Delmas, D., Lizard, G. et al., Antiproliferative activities of resveratrol and related compounds in human hepatocyte derived HepG2 cells are associated with biochemical cell disturbance revealed by fluorescence analyses. Biochimie 2008, 90, 1674-1684.
28. Lancon, A., Delma, D., Osman, H., Thenot, J.-P. et al., Human hepatic cell uptake of resveratrol: involvement of both passive diffusion and carrier-mediated process. Biochem. Biophys. Res. Commun. 2004, 316, 1132-1137.
29. Leone, S., Cornetta, T., Basso, E., Cozzi, R., Resveratrol induces DNA double-strand breaks through human topoisomerase II interaction. Cancer Lett. 2010, 295, 167-172.
30. Hwangbo, K., Zheng, M. S., Kim, Y. J., Im, J. Y. et al., Inhibition of DNA topoisomerases I and II of compounds from Reynoutria japonica. Arch. Pharm. Res. 2012, 35, 1583-1589.
31. Maier-Salamon, A., Bohmdorfer, M., Riha, J., Thalhammer, T. et al., Interplay between metabolism and transport of resveratrol. Ann. N. Y. Acad. Sci. 2013, 1290, 98-106.
32. Pervaiz, S., Holme, A. L., Resveratrol: its biologic targets and functional activity. Antioxid. Redox Signal. 2009, 11, 2851-2897.
33. Gatz, S. A., Wiesmuller, L., Take a break-resveratrol in action on DNA. Carcinogenesis 2008, 29, 321-332.
34. Dickey, J. S., Redon, C. E., Nakamura, A. J., Baird, B. J. et al., H2AX: functional roles and potential applications. Chromosoma 2009, 118, 683-692.
35. Azqueta, A., Collins, A. R., The essential comet assay: a comprehensive guide to measuring DNA damage and repair. Arch. Toxicol. 2013, 87, 949-968.
36. Juan, M. E., Wenzel, U., Daniel, H., Planas, J. M., Resveratrol induces apoptosis through ROS-dependent mitochondria pathway in HT-29 human colorectal carcinoma cells. J. Agric. Food Chem. 2008, 56, 4813-4818.
37. Gonzalez-Sarrias, A., Gromek, S., Niesen, D., Seeram, N. P. et al., Resveratrol oligomers isolated from Carex species inhibit growth of human colon tumorigenic cells mediated by cell cycle arrest. J. Agric. Food Chem. 2011, 59, 8632-8638.
38. Nutakul, W., Sobers, H. S., Qiu, P., Dong, P. et al., Inhibitory effects of resveratrol and pterostilbene on human colon cancer cells: a side-by-side comparison. J. Agric. Food Chem. 2011, 59, 10964-10970.
39. Granados-Principal, S., Quiles, J. L., Ramirez-Tortosa, C. L., Sanchez-Rovira, P. et al., New advances in molecular mechanisms and the prevention of adriamycin toxicity by antioxidant nutrients. Food Chem. Toxicol. 2010, 48, 1425-1438.
40. Raederstorff, D., Kunz, I., Schwager, J. Resveratrol, from experimental data to nutritional evidence: the emergence of a new food ingredient. Ann. N. Y. Acad. Sci. 2013, 1290, 136-141.